The origin of Gilead Sciences, Inc. is not a single founding moment but a complex evolution of scientific discovery, entrepreneurial ambition, and the brutal economics of the global antiviral market. The story begins in 1987 when Michael L. Riordan, a physician and entrepreneur, founded the company in Foster City, California, with an initial focus on developing antifungal therapies for life-threatening infections. Riordan's vision was to create a company that could bring novel, life-saving therapies to patients with limited treatment options, a philosophy that would define the company's culture for decades. The early years of Gilead were marked by significant financial struggles and clinical setbacks, as the company burned through its initial capital reserves while attempting to advance its lead antifungal candidates through Phase I and II trials. By 1992, the company was facing a severe cash crunch and was on the brink of bankruptcy, forcing Riordan to execute a desperate initial public offering that raised $86 million and provided the necessary lifeline to continue operations. The IPO marked a critical inflection point in the company's history, allowing Gilead to shift its focus from antifungals to antivirals, a therapeutic area where the company would eventually achieve global dominance. The strategic pivot was catalyzed by the acquisition of the rights to AmBisome, a liposomal formulation of amphotericin B for fungal infections, which provided the company with its first commercial product and a steady stream of revenue to fund internal discovery efforts. However, the true breakthrough occurred in the late 1990s when Gilead acquired the rights to a novel nucleotide analog platform from a small biotechnology company, a move that would eventually lead to the development of Viread (tenofovir disoproxil fumarate), the first once-daily nucleotide reverse transcriptase inhibitor for HIV. The approval of Viread in 2001 marked the beginning of Gilead's ascent to the top of the global virology hierarchy, establishing the company as a major player in the HIV market and providing the financial foundation for a series of aggressive acquisitions. The $464 million acquisition of Triangle Pharmaceuticals in 2003 secured the rights to emtricitabine, which was combined with tenofovir to create Truvada, the most successful HIV prevention and treatment regimen in history. The subsequent development of Harvoni and Sovaldi for hepatitis C generated over $50 billion in cumulative revenue, transforming Gilead from a niche antiviral player into a global biopharmaceutical powerhouse. The historical context of this transformation is critical to understanding the company's current strategic posture. For the first two decades of its existence, the organization operated as a high-risk, high-reward startup, struggling to achieve commercial scale against entrenched competitors in the HIV and hepatitis B markets. The introduction of the hepatitis C curative therapies in 2013 and 2014 triggered a massive cash windfall that allowed the company to execute a series of transformational acquisitions, including the $11.9 billion purchase of Kite Pharma in 2017 and the $21 billion acquisition of Immunomedics in 2020. These acquisitions fundamentally rewired the company's DNA, shifting its focus from a pure-play virology company to a diversified biopharmaceutical enterprise with significant presence in oncology and inflammatory diseases. This narrative of scientific ambition, strategic risk, and financial discipline defines the modern Gilead Sciences, an organization that has successfully utilized the cash flows from curative hepatitis C therapies to build a diversified biopharmaceutical enterprise capable of competing in the most complex therapeutic areas known to modern medicine.